Rencofilstat + Placebo
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonalcoholic Steatohepatitis (NASH)
Conditions
Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
Trial Timeline
Oct 15, 2022 → Sep 1, 2025
NCT ID
NCT05402371About Rencofilstat + Placebo
Rencofilstat + Placebo is a phase 2 stage product being developed by Hepion Pharmaceuticals for Nonalcoholic Steatohepatitis (NASH). The current trial status is active. This product is registered under clinical trial identifier NCT05402371. Target conditions include Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD.
What happened to similar drugs?
0 of 6 similar drugs in Nonalcoholic Steatohepatitis (NASH) were approved
Approved (0) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
12
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05402371 | Phase 2 | Active |
Competing Products
20 competing products in Nonalcoholic Steatohepatitis (NASH)